<p>Beta Bionics, Inc.（納斯達克代碼：BBNX - 獲取免費報告）週一股價下跌 9.2%，此前華爾街 Zen 將該股票評級從持有下調至賣出。該公司股價最低曾達到 17.83 美元，最後交易價為 18.28 美元。在交易過程中，約有 378,461 股成交，較日均成交量 1,697,192 股下降了 78%。該股票此前收盤價為 20.14 美元。</p>
<p>其他幾位研究分析師最近也對該公司發佈了報告。高盛集團將 Beta Bionics 的目標價從 26.00 美元上調至 33.00 美元，並在 10 月 29 日的研究報告中給予該公司 “買入” 評級。羅伯特·W·貝爾德在 12 月 16 日的報告中設定了 Beta Bionics 的目標價為 28.00 美元。Lake Street Capital 在週五的報告中將 Beta Bionics 的目標價從 35.00 美元上調至 40.00 美元，並給予該公司 “買入” 評級。派珀·桑德勒在 10 月 29 日的報告中重申了 “增持” 評級，並將 Beta Bionics 的目標價設定為 32.00 美元（此前為 26.00 美元）。最後，Truist Financial 在 12 月 18 日的研究報告中將 Beta Bionics 的目標價從 32.00 美元上調至 37.00 美元，並給予該公司 “買入” 評級。一位分析師給予該股票 “強烈買入” 評級，七位給予 “買入” 評級，四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Beta Bionics 的平均評級為 “適度買入”，平均目標價為 30.20 美元。</p>
<p><strong>獲取我們最新的 BBNX 股票分析</strong></p>
<h2>內部活動</h2>
<p>在 Beta Bionics 的其他新聞中，董事 Maria Palasis 在 10 月 31 日的交易中出售了 1,406 股該公司的股票。該股票以平均價格 26.91 美元出售，總交易額為 37,835.46 美元。交易後，該董事在公司持有 9,841 股，價值約為 264,821.31 美元。這代表其持股減少了 12.50%。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，首席財務官 Stephen Feider 在 1 月 2 日的交易中出售了 20,000 股該股票。該股票以平均價格 29.53 美元出售，總價值為 590,600.00 美元。交易完成後，首席財務官持有 42,614 股該公司的股票，價值約為 1,258,391.42 美元。這筆交易代表其持股減少了 31.94%。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士已出售 35,302 股公司股票，價值為 1,036,449 美元。</p>
<h2>對 Beta Bionics 的對沖基金看法</h2>
<p>對沖基金最近買入和賣出了該公司的股票。Divisadero Street Capital Management LP 在第二季度購買了 Beta Bionics 的新股份，價值約為 13,817,000 美元。高盛集團在第一季度購買了 Beta Bionics 的新頭寸，價值約為 715,000 美元。Palumbo Wealth Management LLC 在第二季度購買了 Beta Bionics 的新頭寸，價值約為 431,000 美元。Sands Capital Alternatives LLC 在第二季度將其在 Beta Bionics 的持股增加了 15.0%。Sands Capital Alternatives LLC 現在持有 3,570,113 股該公司的股票，價值為 51,981,000 美元，此前在該期間又購買了 466,331 股。最後，Walleye Capital LLC 在第二季度將其在 Beta Bionics 的持股增加了 47.3%。Walleye Capital LLC 現在持有 218,189 股該公司的股票，價值為 3,177,000 美元，此前在該期間又購買了 70,084 股。</p>
<h2>Beta Bionics 價格表現</h2>
<p>該公司的 50 日移動平均線為 29.28 美元，200 日移動平均線為 22.37 美元。公司的市值為 8.0698 億美元，市盈率為-4.19。</p>
<p>Beta Bionics（納斯達克代碼：BBNX - 獲取免費報告）最後一次公佈季度財報是在 10 月 28 日。該公司報告每股收益（EPS）為-0.33 美元，超出市場共識預期的-0.45 美元，超出幅度為 0.12 美元。Beta Bionics 的淨利潤率為-87.89%，股本回報率為-35.72%。該公司在本季度的收入為 2725 萬美元，而市場共識預期為 2392 萬美元。</p>
<h2>Beta Bionics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Beta Bionics 是一家總部位於馬薩諸塞州波士頓的臨牀階段醫療設備公司，專注於通過自動胰島素輸送解決方案來徹底改變 1 型糖尿病的管理。該公司的旗艦產品 iLet Bionic Pancreas 系統旨在通過根據連續血糖監測數據自動調整胰島素劑量來簡化血糖控制。通過將先進的算法控制與可穿戴輸注泵相結合，iLet 旨在減輕糖尿病管理的日常負擔，並改善患者的臨牀結果。</p>
<p>Beta Bionics 產品的核心是其專有的仿生胰腺軟件，該軟件可以在僅胰島素和雙激素模式下運行。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比 Beta Bionics 更好</li>
<li>你的銀行賬户不再安全</li>
<li>開火正式開始……</li>
<li>請勿刪除，立即閲讀</li>
<li>家族信託如何幫助保護你的財富</li>
<li>在將 AI 數據中心送入軌道的競賽中，早期參與者</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Beta Bionics 嗎？</h2>
<p>在考慮 Beta Bionics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Beta Bionics 並不在名單上。</p>
<p>雖然 Beta Bionics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BBNX

<p>Beta Bionics（納斯達克代碼：BBNX）股價下跌 9.2%，因華爾街 Zen 將該股票評級從持有下調至賣出。該股最低交易價為 17.83 美元，收盤價為 18.28 美元，交易量顯著下降。儘管如此，幾位分析師仍設定了更高的目標價，高盛將其目標價從 26 美元上調至 33 美元。還報告了內部人士的減持，關鍵高管減少了持股。公司報告的季度每股收益為（0.33 美元），超出預期，營收為 2725 萬美元，亦高於預期</p>

<p>Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) shares were down 9.2% on Monday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The company traded as low as $17.83 and last traded at $18.28. Approximately 378,461 shares traded hands during trading, a decline of 78% from the average daily volume of 1,697,192 shares. The stock had previously closed at $20.14.</p>
<div class="lb-trans"><p>Beta Bionics, Inc.（納斯達克代碼：BBNX - 獲取免費報告）週一股價下跌 9.2%，此前華爾街 Zen 將該股票評級從持有下調至賣出。該公司股價最低曾達到 17.83 美元，最後交易價為 18.28 美元。在交易過程中，約有 378,461 股成交，較日均成交量 1,697,192 股下降了 78%。該股票此前收盤價為 20.14 美元。</p>
</div><p>Several other research analysts also recently issued reports on the company. The Goldman Sachs Group upped their price objective on Beta Bionics from $26.00 to $33.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. Robert W. Baird set a $28.00 price target on Beta Bionics in a report on Tuesday, December 16th. Lake Street Capital boosted their price objective on Beta Bionics from $35.00 to $40.00 and gave the company a &#34;buy&#34; rating in a report on Friday. Piper Sandler restated an &#34;overweight&#34; rating and issued a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Finally, Truist Financial increased their price target on Beta Bionics from $32.00 to $37.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Beta Bionics has an average rating of &#34;Moderate Buy&#34; and an average target price of $30.20.</p>
<div class="lb-trans"><p>其他幾位研究分析師最近也對該公司發佈了報告。高盛集團將 Beta Bionics 的目標價從 26.00 美元上調至 33.00 美元，並在 10 月 29 日的研究報告中給予該公司 “買入” 評級。羅伯特·W·貝爾德在 12 月 16 日的報告中設定了 Beta Bionics 的目標價為 28.00 美元。Lake Street Capital 在週五的報告中將 Beta Bionics 的目標價從 35.00 美元上調至 40.00 美元，並給予該公司 “買入” 評級。派珀·桑德勒在 10 月 29 日的報告中重申了 “增持” 評級，並將 Beta Bionics 的目標價設定為 32.00 美元（此前為 26.00 美元）。最後，Truist Financial 在 12 月 18 日的研究報告中將 Beta Bionics 的目標價從 32.00 美元上調至 37.00 美元，並給予該公司 “買入” 評級。一位分析師給予該股票 “強烈買入” 評級，七位給予 “買入” 評級，四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Beta Bionics 的平均評級為 “適度買入”，平均目標價為 30.20 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BBNX</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 BBNX 股票分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other Beta Bionics news, Director Maria Palasis sold 1,406 shares of the company's stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $26.91, for a total transaction of $37,835.46. Following the transaction, the director owned 9,841 shares in the company, valued at approximately $264,821.31. This represents a 12.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company's stock, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 35,302 shares of company stock valued at $1,036,449.</p>
<div class="lb-trans"><p>在 Beta Bionics 的其他新聞中，董事 Maria Palasis 在 10 月 31 日的交易中出售了 1,406 股該公司的股票。該股票以平均價格 26.91 美元出售，總交易額為 37,835.46 美元。交易後，該董事在公司持有 9,841 股，價值約為 264,821.31 美元。這代表其持股減少了 12.50%。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，首席財務官 Stephen Feider 在 1 月 2 日的交易中出售了 20,000 股該股票。該股票以平均價格 29.53 美元出售，總價值為 590,600.00 美元。交易完成後，首席財務官持有 42,614 股該公司的股票，價值約為 1,258,391.42 美元。這筆交易代表其持股減少了 31.94%。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士已出售 35,302 股公司股票，價值為 1,036,449 美元。</p>
</div><h2>Hedge Funds Weigh In On Beta Bionics</h2>
<div class="lb-trans"><h2>對 Beta Bionics 的對沖基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Divisadero Street Capital Management LP purchased a new stake in Beta Bionics during the second quarter valued at approximately $13,817,000. Goldman Sachs Group Inc. purchased a new position in shares of Beta Bionics in the 1st quarter worth approximately $715,000. Palumbo Wealth Management LLC bought a new position in shares of Beta Bionics during the 2nd quarter valued at approximately $431,000. Sands Capital Alternatives LLC raised its holdings in Beta Bionics by 15.0% during the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after buying an additional 466,331 shares during the period. Finally, Walleye Capital LLC raised its holdings in Beta Bionics by 47.3% during the 2nd quarter. Walleye Capital LLC now owns 218,189 shares of the company's stock valued at $3,177,000 after buying an additional 70,084 shares during the period.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該公司的股票。Divisadero Street Capital Management LP 在第二季度購買了 Beta Bionics 的新股份，價值約為 13,817,000 美元。高盛集團在第一季度購買了 Beta Bionics 的新頭寸，價值約為 715,000 美元。Palumbo Wealth Management LLC 在第二季度購買了 Beta Bionics 的新頭寸，價值約為 431,000 美元。Sands Capital Alternatives LLC 在第二季度將其在 Beta Bionics 的持股增加了 15.0%。Sands Capital Alternatives LLC 現在持有 3,570,113 股該公司的股票，價值為 51,981,000 美元，此前在該期間又購買了 466,331 股。最後，Walleye Capital LLC 在第二季度將其在 Beta Bionics 的持股增加了 47.3%。Walleye Capital LLC 現在持有 218,189 股該公司的股票，價值為 3,177,000 美元，此前在該期間又購買了 70,084 股。</p>
</div><h2>Beta Bionics Price Performance</h2>
<div class="lb-trans"><h2>Beta Bionics 價格表現</h2>
</div><p>The business has a 50-day moving average of $29.28 and a 200-day moving average of $22.37. The company has a market capitalization of $806.98 million and a P/E ratio of -4.19.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 29.28 美元，200 日移動平均線為 22.37 美元。公司的市值為 8.0698 億美元，市盈率為-4.19。</p>
</div><p>Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The business had revenue of $27.25 million during the quarter, compared to the consensus estimate of $23.92 million.</p>
<div class="lb-trans"><p>Beta Bionics（納斯達克代碼：BBNX - 獲取免費報告）最後一次公佈季度財報是在 10 月 28 日。該公司報告每股收益（EPS）為-0.33 美元，超出市場共識預期的-0.45 美元，超出幅度為 0.12 美元。Beta Bionics 的淨利潤率為-87.89%，股本回報率為-35.72%。該公司在本季度的收入為 2725 萬美元，而市場共識預期為 2392 萬美元。</p>
</div><h2>Beta Bionics Company Profile</h2>
<div class="lb-trans"><h2>Beta Bionics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.</p>
<div class="lb-trans"><p>Beta Bionics 是一家總部位於馬薩諸塞州波士頓的臨牀階段醫療設備公司，專注於通過自動胰島素輸送解決方案來徹底改變 1 型糖尿病的管理。該公司的旗艦產品 iLet Bionic Pancreas 系統旨在通過根據連續血糖監測數據自動調整胰島素劑量來簡化血糖控制。通過將先進的算法控制與可穿戴輸注泵相結合，iLet 旨在減輕糖尿病管理的日常負擔，並改善患者的臨牀結果。</p>
</div><p>At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.</p>
<div class="lb-trans"><p>Beta Bionics 產品的核心是其專有的仿生胰腺軟件，該軟件可以在僅胰島素和雙激素模式下運行。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Beta Bionics</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Shots officially fired…</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Early-Entry Player in the Race to Put AI Data Centers in Orbit</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Beta Bionics 更好</li>
<li>你的銀行賬户不再安全</li>
<li>開火正式開始……</li>
<li>請勿刪除，立即閲讀</li>
<li>家族信託如何幫助保護你的財富</li>
<li>在將 AI 數據中心送入軌道的競賽中，早期參與者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Beta Bionics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Beta Bionics 嗎？</h2>
</div><p>Before you consider Beta Bionics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Beta Bionics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Beta Bionics 並不在名單上。</p>
</div><p>While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Beta Bionics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Beta Bionics（NASDAQ:BBNX）股價下跌 9.2%，因分析師下調其評級